Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Inv. presentation

Mersana Therapeutics, Inc. (MRSN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 4 Huber Martin H. Jr. (President, CEO) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 9,102 options to buy @ $1.26, valued at $11.5k
10/04/2023 4 Dere Willard H (Director) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 11,011 shares @ $0
10/04/2023 4 Hege Kristen (Director) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 9,523 options to buy @ $1.26, valued at $12k
10/04/2023 4 Alleva Lawrence M (Director) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 14,047 options to buy @ $1.26, valued at $17.7k
10/04/2023 4 MOTT DAVID M (Director) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 15,873 shares @ $0
08/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Mersana Therapeutics Announces Second Quarter 2023 Financial Results"
08/07/2023 SC 13G Venrock Healthcare Capital Partners III, L.P. reports a 8.5% stake in Mersana Therapeutics, Inc.
07/31/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
07/27/2023 SC 13G EcoR1 Capital, LLC reports a 16.9% stake in Mersana Therapeutics, Inc.
07/27/2023 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Ot...
Docs: "Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization"
07/06/2023 4 Alleva Lawrence M (Director) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 5,391 options to buy @ $3.42, valued at $18.4k
07/06/2023 4 Huber Martin H. Jr. (Director) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 4,477 options to buy @ $3.42, valued at $15.3k
07/06/2023 4 Hege Kristen (Director) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 3,654 options to buy @ $3.42, valued at $12.5k
07/06/2023 4 Dere Willard H (Director) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 4,217 shares @ $0
07/06/2023 4 MOTT DAVID M (Director) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 6,079 shares @ $0
06/12/2023 4 Hack Andrew A. F. (Director) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 14,467 shares @ $0
Granted 18,355 options to buy @ $8.64, valued at $158.6k
06/12/2023 4 Diaz Allene M. (Director) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 14,467 shares @ $0
Granted 18,355 options to buy @ $8.64, valued at $158.6k
06/12/2023 4 Hege Kristen (Director) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 14,467 shares @ $0
Granted 18,355 options to buy @ $8.64, valued at $158.6k
06/12/2023 4 Huber Martin H. Jr. (Director) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 14,467 shares @ $0
Granted 18,355 options to buy @ $8.64, valued at $158.6k
06/12/2023 4 MOTT DAVID M (Director) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 14,467 shares @ $0
Granted 18,355 options to buy @ $8.64, valued at $158.6k
06/12/2023 4 Alleva Lawrence M (Director) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 14,467 shares @ $0
Granted 18,355 options to buy @ $8.64, valued at $158.6k
06/12/2023 4 Dere Willard H (Director) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 14,467 shares @ $0
Granted 18,355 options to buy @ $8.64, valued at $158.6k
06/09/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MERSANA THERAPEUTICS, INC."
05/09/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results"
04/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/14/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/05/2023 4 Hege Kristen (Director) has filed a Form 4 on Mersana Therapeutics, Inc.
Txns: Granted 3,451 options to buy @ $4.25, valued at $14.7k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy